A Combination of Cabozantinib and Radiation Does Not Lead to an Improved Growth Control of Tumors in a Preclinical 4T1 Breast Cancer Model

The tyrosine kinase inhibitor Cabozantinib has been applied in clinical studies in combination with radiotherapy. We investigated the effect of such combination on triple-negative 4T1 cells as a metastatic breast cancer model in vitro and in vivo upon inoculation in BALB/c mice. In vitro assays indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Reppingen, Norman, Helm, Alexander, Doleschal, Laura, Durante, Marco, Fournier, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692262/
https://www.ncbi.nlm.nih.gov/pubmed/34956902
http://dx.doi.org/10.3389/fonc.2021.788182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692262/
https://www.ncbi.nlm.nih.gov/pubmed/34956902
http://dx.doi.org/10.3389/fonc.2021.788182

Ejemplares similares